Key facts
- It has raised $33.9M; the latest was Later Stage VC in Oct 2025.
- Notable investors include IMM Investment, Mirae Asset Capital, Axis Investment, Atinum Investment, Company K Partners — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Innovo Therapeutics (Drug Discovery)
- ·The full record, as it builds
Funding rounds
No funding rounds for Innovo Therapeutics (Drug Discovery) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Innovo Therapeutics (Drug Discovery)
Developer of an artificial intelligence drug research and development platform designed to discover new drugs that improve the quality of human life. The company's platform uses real-time convergence of practical drug development experience and virtual drug discovery and is based on machine learning, target discovery, and toxicity prediction, enabling healthcare professionals to offer treatments for fibrosis, immune, and inflammatory diseases.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2019
- Website
- innovothera.co.kr/
- Ownership
- Privately Held (backing)
Innovo Therapeutics (Drug Discovery) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Innovo Therapeutics (Drug Discovery) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Innovo Therapeutics (Drug Discovery) in its N-PORT filings yet. We sweep new filings monthly.